VFI supports Sars-Cov-2 vaccine development through TRANSVAC2 (European Commission)

As partner of TRANSVAC2, VFI offers its adjuvant and formulation services to vaccine researchers and developers in the context of Covid-19. Vaccine researchers and developers can ship their Sars-Cov-2 vaccine antigens to VFI for formulation with adjuvants suitable for clinical use. Once optimal formulations are identified, VFI can perform immunogenicity studies in mice including analyses of B- and T-cell responses. First deadline for application is 15 April 2020.

Share on linkedin
Share on reddit
Share on facebook
Share on twitter
Share on email